LIXTE pivots to AI power infrastructure as NERC flags 224 GW demand gap

LIXTE Biotechnology Holdings Inc. is abandoning drug development to build an AI energy infrastructure equipment and services platform, tapping a market that grid regulators say faces a 224-gigawatt supply shortfall over the next decade.

"The power problem is the AI problem," Chief Executive Officer Geordan Pursglove said. "Compute capacity is being built faster than the grid can support it. Hyperscale operators, sovereign AI programs and next-generation inference applications all face the same constraint: reliable power."

The North American Electric Reliability Corp. in January projected summer peak demand will rise by 224 GW over 10 years, and in April issued a rare Level 3 Alert directing grid operators to address reliability risks tied to large-scale computational loads. LIXTE plans to focus on power equipment and service solutions for hyperscale AI campuses, including long-duration generation and grid-edge infrastructure, as well as distributed systems for enterprise AI and edge deployments.

The company, which trades on Nasdaq under the ticker LIXT, said it will seek a strategic buyer for its clinical-stage pharmaceutical and med-tech operations, including its lead cancer compound LB-100 and its Liora Technologies proton therapy subsidiary. It expects to maintain its listing throughout the transition.

Denham Capital's Porter Joins Board

Stuart D. Porter, founder of Denham Capital Management LP, will join LIXTE's board effective immediately. His firm has overseen more than $12 billion in invested and committed capital across energy and energy-transition sectors since 2004. Denham's infrastructure group is advancing a roughly 10 GW pipeline of AI data-center-oriented power generation opportunities in the US and Europe.

"This is a generational dislocation between compute demand and reliable, dispatchable power," Porter said. "The anticipated AI build-out will require disciplined capital allocation, operational execution and long-duration infrastructure investment."

Porter's appointment adds credibility to a pivot that requires significant capital. Denham's experience developing, building and financing large-scale gas, renewable and storage projects globally gives LIXTE a potential sourcing advantage for acquisitions and partnerships targeting advanced generation technologies.

The AI Power Bottleneck

The widening gap between North American electricity demand and available generation capacity is reshaping how hyperscalers plan data center construction. Amazon, Microsoft and Google have all announced multi-billion-dollar power procurement deals in the past year, with some projects facing interconnection delays of four to seven years.

LIXTE's strategy targets the equipment and service layer of that bottleneck rather than competing directly with utilities or independent power producers. The company plans to pursue strategic acquisitions to build out its capabilities, though it has not disclosed specific targets or the size of any associated financing.

For investors, the question is whether LIXTE can execute a transformation that few small-cap companies have attempted. The company's market capitalization and cash position were not disclosed in the announcement, and the timeline for completing the pharma divestiture remains unclear. Denham's involvement signals institutional backing, but the success of the pivot will depend on LIXTE's ability to acquire and integrate power infrastructure assets in a market where competition for deals is intensifying.

This article is for informational purposes only and does not constitute investment advice.